34622-39-4

Basic information

• Product Name: (S)-2-PIPERIDINONE-6-CARBOXYLIC ACID
• Synonyms: 6-OXO-L-PIPECOLIC ACID;(S)-2-PIPERIDINONE-6-CARBOXYLIC ACID;(S)-2-PIPERIDONE-6-CARBOXYLIC ACID;(S)-6-OXO-2-PIPERIDINECARBOXYLIC ACID;(S)-6-OXO-PIPERIDINE-2-CARBOXYLIC ACID;PYRO-L-ALPHA-AMINOADIPIC ACID;6-Oxo-L-pipecolic acid, (S)-2-Piperidone-6-carboxylic acid, L-Pyrohomoglutamic acid;(S)-Piperidinone-6-carboxylic acid
• CAS NO: 34622-39-4
• Molecular Formula: C₆H₉NO₃
• Molecular Weight: 143.14
• Mol File: 34622-39-4.mol
• Article Data: 13

Chemical Properties

• Melting Point: 129-134 °C
• Boiling Point: 436.964 °C at 760 mmHg
• Flash Point: 218.068 °C
• Appearance: /
• Density: 1.287 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.499
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Aqueous Acid (Sparingly, Heated, Sonicated), DMSO (Slightly, Heated)
• PKA: 3.59±0.20(Predicted)
• CAS DataBase Reference: (S)-2-PIPERIDINONE-6-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-PIPERIDINONE-6-CARBOXYLIC ACID(34622-39-4)
• EPA Substance Registry System: (S)-2-PIPERIDINONE-6-CARBOXYLIC ACID(34622-39-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 2
• Hazardous Substances Data: 34622-39-4(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 34622-39-4 differently. You can refer to the following data:
1. 6-Oxo-L-pipecolic Acid is an intermediate in the synthesis of metabolites of lysine developed during aging and in diabetic patients.
2. (S)-6-Oxo-2-piperidinecarboxylic acid can be used as a reactant to synthesize: Functionalized β-lactam N-heterocycles via carboxymethylproline synthase catalyzed cyclization reactions. Pro-(S)-C5 branched [4.3.1] aza-amide bicycles as potential inhibitors for FK506-binding proteins. Ethyl (S)-2-(6-oxopiperidin-2-yl)acetate, which is reduced using LiBH4 to produce optically pure hydroxymethyl lactams.

InChI:InChI=1/C6H9NO3/c8-5-3-1-2-4(7-5)6(9)10/h4H,1-3H2,(H,7,8)(H,9,10)/t4-/m0/s1

Upstream product

• 1118-90-7 L-homoglutamic acid 
• 2389-60-8 Z-Lys(Boc)-OH 
• 82228-90-8 N^α-benzyloxycarbonyl-N^ε-tert-butyloxycarbonyl-L-lysine isopropyl ester 
• 47307-39-1 N^α-benzyloxycarbonyl-L-lysine isopropyl ester 
• 82228-91-9 isopropyl α-benzyloxycarbonylamino-ε-oxohexanoate 
• 2418-95-3 (S)-2-amino-6-(tert-butoxycarbonylamino)hexanoic acid 
• 83793-27-5 L-2-amino-5-<(benzyloxycarbonyl)carbamoyl>pentanoic acid 
• 102922-72-5 (S)-2-(((benzyloxy)carbonyl)amino)-6-hydroxyhexanoic acid 
• 24325-14-2 (2S)-2-[(phenylmethoxy)carbonyl]aminoadipic acid 
• 1155-64-2 N₆-[(benzyloxy)carbonyl]-L-lysine 
• 6033-32-5 (S)-2-amino-6-hydroxyhexanoic acid 

Downstream Products

• 77897-79-1 <*>Aad-His(DNP)-Tzl-NH2 
• 128726-47-6 (+)-(S)-6-hydroxymethyl-2-piperidinone 
• 259225-90-6 benzyl 6-oxopipecolate 
• 1448348-05-7 (S)-N-(1-(2-Chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-N-(3-fluoro-phenyl)-6-oxopiperidine-2-carboxamide 
• 1456892-30-0 (1R,3S,6S)-tert-butyl 3-(aminomethyl)-2-azabicyclo[4.1.0]heptane-2-carboxylate 
• 1456892-90-2 4-bromo-3-((1S,3S,6R)-3-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)-2-azabicyclo[4.1.0]heptane-2-carbonyl)benzonitrile 
• 1456892-92-4 C₂₁H₂₁F₃IN₃O 
• 1456892-94-6 C₂₀H₁₈ClF₃IN₃O 
• 1456892-96-8 C₂₁H₂₁F₃IN₃O 
• 1456892-06-0 (2-methyl-5-phenylthiazol-4-yl)((1R,3S,6S)-3-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)-2-azabicyclo[4.1.0]heptan-2-yl)methanone 
• 1456892-16-2 (5-methyl-2-(pyrimidin-2-yl)phenyl)((1S,3S,6R)-3-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)-2-azabicyclo[4.1.0]heptan-2-yl)methanone 
• 1456892-17-3 (5-chloro-2-(pyrimidin-2-yl)phenyl)((1S,3S,6R)-3-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)-2-azabicyclo[4.1.0]heptan-2-yl)methanone 
• 1456892-25-3 (2-methyl-5-phenylthiazol-4-yl)((1S,3S,6R)-3-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)-2-azabicyclo[4.1.0]heptan-2-yl)methanone 
• 78664-73-0 L-pyro-2-aminoadipyl-L-leucyl-L-prolinamide 

Relevant articles and documents

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.